We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Angle plc (AGL) Ordinary 10p

Sell:9.20p Buy:10.00p 0 Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.20p
Buy:10.00p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.20p
Buy:10.00p
Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.

Contact details

Address:
The Surrey Research Park, 10 Nugent Road
GUILDFORD
GU2 7AF
United Kingdom
Telephone:
+44 (01483) 343434
Website:
https://www.angleplc.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 26 September 2024 26/09/24
AGM 11 July 2024 11/07/24
AGM 10 July 2024 10/07/24
Annual report 18 June 2024 18/06/24
Final results 05 June 2024 05/06/24

General stock information

EPIC:
AGL
ISIN:
GB0034330679
Market cap:
£30.96 million
Shares in issue:
322.53 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Andrew Newland
    Chief Executive, Executive Director
  • Ian Griffiths
    Chief Financial Officer, Finance Director, Executive Director, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.